PatientsVille.com Logo


Hpv Medical Research Studies

Up-to-date List of Hpv Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Hpv Medical Research Studies

Rank Status Study
1 Unknown  KAP/WTP and Hpv Prevalence Studies in a Developing World Setting (Bamako, Mali)
Condition: Human Papillomavirus
Outcome Measures: Prevalence of Hpv subtypes associated with cervical cancer;   Knowledge, Attitudes and Practices (KAP) and Willingness To Participate (WTP) in an Hpv vaccine study;   Determine usability of Gardasil in West Africa
2 Recruiting Transmission Reduction and Prevention With Hpv Vaccination (TRAP-Hpv) Study
Condition: Human Papillomavirus Infection
Intervention: Biological: Hpv vaccine, Gardasil
Outcome Measure: The primary outcome will be the reduction of Hpv DNA positivity for the target Hpv vaccine types (i.e., Hpvs 6, 11, 16, and 18) in multiple anatomic sites in the placebo-treated sexual partners of persons who received Gardasil.
3 Recruiting Educational Intervention to Minimize Disparities in Humanpapillomavirus Vaccination
Condition: Hpv Vaccination Status
Interventions: Behavioral: Tailored educational materials;   Behavioral: Untailored educational materials;   Behavioral: Survey-only
Outcome Measures: Quality of the Hpv vaccine decision among parents/patients;   Likelihood of Hpv vaccination among patients
4 Unknown  Distribution of Human Papillomavirus (Hpv) Genotypes in Patients With Cervical Cancer From Croatia
Condition: Cervical Cancer
Outcome Measures: Pre-vaccination distribution of Hpv genotypes in women with HSIL and invasive cervical carcinoma;   Hpv vaccine coverage in Croatia
5 Recruiting Monitoring of Oral Human Papillomavirus Infection (Hpv) in Hpv-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Conditions: Carcinoma, Squamous Cell;   Head and Neck Neoplasms;   Oropharyngeal Neoplasms
Intervention: Other: Assessment of Oral Hpv Infection
Outcome Measures: Proportion of patients with Hpv-positive OPSCC undergoing CRT who are clear of their oral Hpv infection at each time-point;   Time to Hpv clearance for patients with Hpv-positive OPSCC undergoing CRT;   Number of aneuploidy cells as measured by FISH (Florescent in-situ hybridization) and the mRNA copy number for Hpv E6 and Hpv E7 at each time-point;   Clinical outcomes of interest (local control, loco-regional control, distant metastasis-free survival, and overall survival (OS)) in patients with Hpv-positive OPSCC undergoing CRT
6 Recruiting Window of Opportunity Trial of ADXS 11-001 Vaccination Prior to Robotic Surgery of Hpv-Positive Oropharyngeal Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma
Intervention: Biological: ADXS11-001 (ADXS-Hpv)
Outcome Measures: change in Hpv E6/E7-specific CD8+ cytotoxic lymphocyte (CTL) responses;   Toxicity;   Vaccine induced Hpv E6/E7specific CD8+ CTL responses
7 Unknown  Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (Hpv) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule
Condition: Human Papillomavirus (Hpv) Vaccine
Intervention: Biological: Hpv-16/18 L1 VLP AS04 vaccine
Outcome Measures: To assess the occurrence of serious adverse events (SAEs) throughout the study;   To evaluate the occurrence of solicited local and solicited general symptoms and the occurrence of unsolicited symptoms as well as the occurrence of medically significant conditions.
8 Recruiting Evaluation of Immune Response Against Human Papillomavirus (Hpv)in Patients With Metastatic Cancer of the Anal Canal
Conditions: Metastatic Anal Canal Cancer;   Human Papillomavirus
Intervention: Drug: DCF regimen
Outcome Measures: presence and characterization of anti-Hpv immune responses in patients in complete remission;   global survival;   progression free survival
9 Recruiting Phase II Study of Hpv Therapeutic Vaccine in Hpv Infected Women With Normal Cytology or ASCUS/LSIL
Conditions: Genital Infection Viral;   HUMAN PAPILLOMA VIRUS
Interventions: Biological: ProCervix;   Biological: Placebo
Outcome Measures: Clearance of Hpv 16 and Hpv 18 infection at Month 12 using a type specific, sensitive and quantitative Hpv PCR assay.;   Clearance of Hpv 16 and Hpv 18 infection.
10 Recruiting The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (Hpv) Types 6, 11, 16, and 18 (Hpv-6/11/16/18) in Chronic Kidney Disease (CKD) Patients
Conditions: Chronic Kidney Disease, Stage IV (Severe);   Chronic Kidney Disease, Stage V
Intervention: Biological: Hpv-6/11/16/18 vaccine
Outcome Measures: Titers of neutralizing antibodies for each Hpv type;   Seroconversion rate;   Titer of neutralizing antibody of each Hpv type;   seroconversion rate
11 Unknown  A Study to Compare the Impact of a School Based Hpv Program on Vaccination Uptake and Completion Rates
Condition: Human Papillomavirus
Interventions: Other: Hpv Vaccine and Disease Education;   Other: Reduction of barriers;   Other: Survey
Outcome Measures: Change in number of participants, by gender, who receive Hpv vaccination;   Change in number of participants, by gender, who complete the Hpv vaccination series
12 Not yet recruiting Primary and Secondary Prevention of Human Papillomavirus (Hpv) Disease in China
Conditions: Hpv Infections;   Precancerous Disease of the Cervix;   Cervical Cancer;   Hpv Related Diseases
Intervention: Biological: Gardasil (VLP, Hpv Quadrivalent prophylactic vaccine)
Outcome Measures: The quadrivalent Hpv vaccine can prevent Hpv naive girls at baseline from being infected at least on a five year follow-up and longer.;   Knowledge of Hpv and the link between Hpv and cervical cancer;   Attitudes towards Hpv vaccine;   Attitudes towards sex and the proper age of sexual debut;
13 Unknown  Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults
Conditions: Hpv;   HIV
Intervention: Biological: Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)
Outcome Measures: type specific antibody titers for Hpv types 6, 11, 16 and 18 at one month after completion of Hpv vaccine series (T3) in HIV infected subjects vs. healthy subjects;   antibody Hpv titers to types 6, 11, 16 and 18, one month after the first two vaccination series (T1 and T2) in HIV-infected subjects vs healthy subjects;   antibody titers to Hpv types 6, 11, 16 and 18 at month 12(T4)and 18 (T5)from baseline (T0).;   local and systemic adverse events;   HIV viral load and lymphocyte CD4+ count;   lymphoproliferative responses, cytokine production and immunophenotype analysis of lymphocyte subpopulations
14 Not yet recruiting ASPIRE Pilot: Comparing Self-collected Hpv Testing With Visual Inspection With Acetic Acid Screening for Cervical Cancer
Condition: Cervical Cancer
Interventions: Procedure: Hpv self-colleciton;   Procedure: visual inspection with acetic acid (VIA);   Drug: 3-5% acetic acid
Outcome Measures: Histologically confirmed cervical intra-epithelial lesions grade 2 (CIN2) or greater in self-collected Hpv arm and VIA arm at 12 months by colposcopy;   Uptake of Hpv self-collection compared to VIA in women in Kampala, Uganda;   Prevalence rates of high-risk Hpv in the self-collection arm.;   Assess screen positive rates by nurse-midwife exam in VIA arm;   Evaluation of adverse events or complications documented at time of sample collection, 4-6 weeks after cryotherapy and at 12 and 36 months by study questionnaire
15 Unknown  Anal Human Papillomavirus in Inflammatory Bowel Disease Study
Conditions: Inflammatory Bowel Disease (IBD);   Ulcerative Colitis (UC);   Crohn's Disease (CD);   Anal Human Papillomavirus
Intervention: Procedure: Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples
Outcome Measures: Presence or absence of Hpv types 6, 11, 16, 18, 31, 33, 45, 52, 58;   Quantification of Hpv types 6, 11, 16, 18, 31, 33, 45, 52, 58;   Anal cytology grade (normal, ASC-US, ASC-H, LSIL, HSIL, cancer);   Anal biopsy grade (normal, AIN-1, AIN-2/AIN-3, cancer);   Number of discrete high-grade anal dysplasia lesions
16 Unknown  Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease
Conditions: Juvenile Idiopathic Arthritis;   Systemic Lupus Erythematosus;   Juvenile Dermatomyositis
Intervention: Drug: Human papilloma virus vaccine (cervarix)
Outcome Measures: the immunogenicity of Hpv vaccination in patients with immune system disorders. The immunogenicity of Hpv vaccination in patients will be compared to healthy controls, measured by antibody levels against Hpv serotype 16 & 18.;   difference in the activity of underlying disease before versus after vaccination. A difference in the activity of underlying autoimmune disease, will be measured according to specific criteria for each autoimmune disease.
17 Recruiting Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent(Type 16/18 )Vaccine
Conditions: Cervical Intraepithelial Neoplasia;   Cervical Cancer;   Vaginal Intraepithelial Neoplasia;   Vulvar Intraepithelial Neoplasia;   Persistent Infection
Interventions: Biological: Hpv Vaccine;   Biological: HEV vaccine
Outcome Measures: Number of Subjects With Histopathologically-confirmed CIN2+ and/or VIN2+ and/or VaIN2+ Associated With Hpv-16 and/or -18 Cervical Infection;   Number of Subjects With Hpv-16 and/or -18 persistent cervical infection(6-month+ definition);   Number of Subjects Reporting Solicited Local and General Symptoms;   Number of Subjects Reporting Unsolicited Adverse Events;   Number of Subjects Reporting Serious Adverse Events (SAEs);   number of subjects with persistent cervical infection (12-month+ definition)associated with Hpv-16 and/or Hpv-18;   number of subjects Histopathologically-confirmed CIN1+ and/or VIN1+ and/or VaIN1+ associated with Hpv-16 and/or -18 cervical infection;   number of subjects with incidence infection associated with Hpv-16 and/or Hpv-18;   Anti-Hpv16 and anti-Hpv18 seroconversion rates and geometric mean concentrations at Months 7
18 Recruiting Effectiveness, Safety and Immunogenicity of GSK Biologicals' Hpv Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents
Condition: Infections, Papillomavirus
Interventions: Biological: GSK Biologicals' Hpv Vaccine GSK580299;   Biological: Engerix-B™
Outcome Measures: Hpv-16 and/or Hpv-18 DNA positivity (by PCR) in females approximately 18.5 years of age in Arm B vs. C.;   Hpv-16 and/or Hpv-18 DNA positivity (by PCR) in females approximately 18.5 years of age in Arm A vs. C.;   Hpv-16 and/or Hpv-18 DNA positivity (by PCR) in females approximately 18.5 years of age in Arm A vs. B.;   Oncogenic Hpv DNA positivity (by PCR) (overall and individually) in females approximately 18.5 years of age.;   Oropharyngeal Hpv-16 and/or Hpv-18 DNA positivity (by PCR) in females in Arms A, B and C.;   Oropharyngeal oncogenic Hpv DNA positivity (by PCR) in females in Arms A, B, and C.;   Occurrence, intensity and causal relationship to vaccination of solicited (local and general) symptoms in a subset of subjects.;   Occurrence, intensity and causal relationship to vaccination of unsolicited symptoms in a subset of subjects.;   Occurrence of rash and urticaria in a subset of subjects.;   Occurrence of medically significant conditions in a subset of subjects;   Occurrence and causal relationship to vaccination of SAEs in a subset of subjects.;   Occurrence of SAEs assessed by the investigator as possibly related to vaccination in all subjects.;   Occurrence of new onset of autoimmune diseases between Visit 1 and Visit 5 retrieved from Care Register for Social Welfare and Health (HILMO) (all study participants).;   Occurrence of pregnancies with onset, and their outcomes, retrieved from medical birth registry.;   Anti-Hpv-16/18 antibody levels and quality assessed at the time of serum withdrawal in a subset of subjects.
19 Unknown  Hpv Vaccine Acceptability Among Young Men Who Have Sex With Men
Conditions: Hpv Vaccine Attitudes;   Hpv Vaccine Intention
Outcome Measures: Hpv vaccine acceptability;   Attitudes towards Hpv vaccination
20 Recruiting MeFirst: A Tailored Intervention to Hpv Vaccine Decision Making
Condition: Hpv
Intervention: Behavioral: MeFirst Tailored Intervention
Outcome Measures: Determine the effect of Me First, a tailored, online Hpv vaccination decision-making guide on Hpv vaccination intention and/or uptake.;   Determine the effect of Me First on Hpv-related knowledge.

These studies may lead to new treatments and are adding insight into Hpv etiology and treatment.

A major focus of Hpv research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Hpv